BeOne Medicines (ONC) Stock: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$346.51
4.71 (1.38%)
â˛
5d:
-4.46%
30d:
-3.49%
90d:
+33.13%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ONC is fairly priced but lacks strong directional signals. At -3.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ONC is fairly priced but lacks strong directional signals. At -3.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$500.66
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$310.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $346.51, which is considered slightly low relative to its 30-day fair value range of $343.45 to $372.03. The stock's valuation (Forward PE: 33.7) is in line with its historical norms (37.1). Remarkably, the market is currently pricing in an annual earnings decline of 3.2% over the next few years. This pessimistic expectation contrasts with the company's recent 166.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is currently testing key support at $336.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ONC scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $432.16 (+24.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is currently testing key support at $336.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ONC scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $432.16 (+24.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$343.45 -
$372.03
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.7% below Wall St target ($432.16)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$343.45 -
$372.03
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$336.95
Resistance Level
$372.00
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.69
Wall Street Target
$432.16
(+24.7%)
Revenue Growth (YoY)
29.6%
Earnings Growth (YoY)
166.7%
Profit Margin
10.7%
Valuation Discount vs History
-3.2% cheaper
PE vs Historical
33.7 vs 37.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.2%
(market-implied from PE analysis)
1-Year Target
$335.42
(-3%)
2-Year Target
$324.69
(-6%)
3-Year Target
$314.30
(-9%)
3-Yr Target (if PE normalizes)
(PE: 34â37)
$346.07
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.7, Growth: 35.4%)
$859.33
(+148%)
Base:
(SPY PE: 20.2, Growth: 35.4%)
$514.41
(+49%)
Bear:
(PE: 17.1, Growth: 35.4%)
$437.25
(+26%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Forward PE: 33.90 | Forward EPS (Implied): $10.22
Bull Case
$418.41
(+21%)
Analyst growth 15.0%, PE expands to 35.6
Base Case
$346.51
(0%)
Market implied 0.0%, PE stable at 33.9
Bear Case
$265.08
(-24%)
Severe decline -15.0%, PE contracts to 30.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 33.7 to 37.1
Stabilization Target:
$381.53
(+10.1%)
PE Expansion Potential:
+10.1%
Share & Embed Analysis
Last updated: September 12, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |